HIGHLIGHTS
- who: Series Editors Amy B. and collaborators from the DepartmentNorthwestern University, Chicago, Illinois, USA have published the paper: REVIEW SERIES: IMMUNE ENVIRONMENT IN GLIOBL ASTOMA, in the Journal: (JOURNAL)
- what: TAMs are highly infiltrated in GBM tumors and substantially contribute to tumor progression, immunosuppression, and treatment resistance (12, 24, 40).
- future: Although further studies are needed to evaluate the antitumor efficiency of CCL2/CCR2 axis blockade in GBM patients it is worth noting that CCL2 neutralizing antibody (e_g carlumab) shows a modest effect in patients with prostate cancer . These findings highlight that additional . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.